TC Biopharm HoldingsTCBWFPreferred / convertible
13F holders, Q4 2024 (December 31)6holders
2new positions
2sold out
$0.01avg. 13F price*
At the end of Q4 2024, 6 institutions reported holding TC Biopharm Holdings Ltd. (TCBWF) in their 13F filings, unchanged from Q3 2024. 2 opened new positions and 2 sold out. The largest holders were Wolverine Asset Management LLC ($7K), Kepos Capital LP ($5K) and Nantahala Capital Management, LLC ($2K).
- Company
- TC Biopharm Holdings Ltd.
- CUSIP
- 87807D111
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $7K |
| Exits | 2 | $344 |
All 13F filers, Q3 2024 → Q4 2024: 674,731 shares bought and 18,894 shares sold, net +655,837 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| Wolverine Asset Management LLC | — | New | 668,324 | $7K |
| Kepos Capital LP | — | No change | 470,588 | $5K |
| Nantahala Capital Management, LLC | — | No change | 235,294 | $2K |
| Csenge Advisory Group | — | Add +26.5% | 23,862 | $236 |
| UBS Group AG | — | Add +103.2% | 2,400 | $24 |
| Armistice Capital, LLC | — | New | 188 | $2 |
"% of holder's portfolio" is TCBWF's weight in each manager's 13F, not the share of TC Biopharm Holdings Ltd. the manager owns.